Reaction

Scleroderma reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,598 reports · 76 co-occurring drugs

As of the last recalculation, Scleroderma appears in 3,598 FAERS reports alongside 76 co-occurring drug terms. The strongest observed disproportionality signal is SELEXIPAG (PRR 36.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Selexipag	156	36.5	36.7
Epoprostenol	75	33.8	34.0
Bosentan	252	31.0	31.2
Ambrisentan	561	30.6	30.7
Macitentan	305	27.7	27.9
Treprostinil	450	23.6	23.6
Tadalafil	353	22.5	22.6
Sildenafil	212	22.4	22.5
Sirolimus	48	20.9	20.9
Sildenafil Powder,	114	19.1	19.2
Sildenafil Citrate	340	17.0	17.0
0Xygen	137	16.7	16.7
Oxygen	137	16.7	16.7
Imatinib	50	16.6	16.7
Riociguat	88	16.0	16.0
Nintedanib	78	14.7	14.7
Bleomycin Sulfate	22	12.4	12.4
Nifedipine	98	12.3	12.3
Mycophenolate Mofetil	251	11.4	11.4
Mycophenolate Mofetil Hydrochloride	251	11.4	11.4
Tacrolimus Ointment 0.1%	162	7.8	7.8
Tacrolimus Extended-Release Capsules	162	7.8	7.8
Cyclosporine	136	7.3	7.3
Mycophenilic Acid	26	7.3	7.3
Metolazone	14	7.2	7.2
Tacrolimus	176	6.8	6.8
Mycophenolic Acid	36	6.6	6.6
Captopril	10	6.0	6.0
Posaconazole Delayed-Release	11	5.8	5.8
Hyoscyamine Sulfate	9	5.7	5.7
Bumetanide	25	5.5	5.5
Torsemide	30	5.3	5.3
Azathioprine	78	5.2	5.2
Blinatumomab	9	5.0	5.0
Epoetin Alfa	10	4.9	4.9
Paclitaxel (Aibumin-Bound)	68	4.9	4.9
Ibrutinib	64	4.6	4.7
Ganciclovir	8	4.5	4.5
Ruxolitinib	54	4.4	4.4
Dexlansoprazole	31	4.3	4.3
Paclitaxel	72	4.3	4.3
Rituximab	151	4.3	4.3
Conjugated Estrogens And Medroxyprogesterone Acetate	17	4.2	4.2
Calcium, Magnesium, Potassium, And Sodium Oxybates	6	4.0	4.0
Posaconazole	11	3.9	3.9
Hydroxychloroquine Sulfate	61	3.9	3.9
Ursosiol	13	3.9	3.9
Pemetrexed Disodium	25	3.8	3.8
Pemetrexed	14	3.8	3.8
Azelastine	11	3.6	3.6
Fludarabine Phosphate	23	3.4	3.4
Eculizumab	30	3.2	3.2
Pertuzumab	15	3.2	3.2
Tolvaptan	8	3.2	3.2
Docetaxel Anhydrous	36	3.1	3.1
Docetaxel	36	3.1	3.1
Tiotropium Bromide Inhalation Spray	6	3.1	3.1
Gemcitabine Hydrochloride	28	3.1	3.1
Gemcitabine	20	2.9	2.9
Imatinib Mesylate	13	2.7	2.7
Romiplostim	7	2.7	2.7
Brinzolamide	4	2.7	2.7
Pembrolizumab	45	2.5	2.5
Rifaximin	9	2.5	2.5
Rocuronium Bromide	5	2.5	2.5
Ravulizumab	5	2.1	2.1
Belimumab	11	2.0	2.0
Atezolizumab	13	1.9	1.9
Nivolumab	32	1.9	1.9
Botulinum Toxin Type A	4	1.9	1.9
Medroxyprogesterone Acetate	16	1.9	1.9
Pseudoephedrine Hydrochloride	3	1.7	1.7
Pseudoephedrine Hcl	3	1.6	1.6
Durvalumab	5	1.4	1.4
Pirfenidone	9	1.3	1.3
Erenumab-Aooe	10	1.1	1.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.